Combination chemotherapy for advanced colorectal cancer. A pilot study

K. J. Pandya, A. Y.C. Chang, R. Qazi, J. Rubins, R. Asbury

Research output: Contribution to journalArticle

Abstract

Twenty-three patients with advanced colorectal carcinoma, mostly with liver and lung metastases and measurable disease, were treated with mitomycin-C 20 mg/m2 I.V. and vincristine 1.2 mg/m2 I.V. every 6 weeks, and cisplatinum 50 mg/m2 I.V. and 5-fluorouracil 1,000 mg/m2/24 hours I.V. continuous infusion for 96 hours every 3 weeks based upon the hypothesis that cisplatinum may potentiate the antitumor activity of antimetabolites and alkylating agents. Five patients had received prior chemotherapy and six had received prior radiotherapy, with one of these patients receiving both. One complete and 10 partial responses were observed, with an overall response rate of 48% (90% confidence interval 30-70%). The toxicity was manageable. A possible potentiating effect of cisplatinum is suggested in this first attempt in the treatment of colorectal cancer, and warrants further exploration.

Original languageEnglish (US)
Pages (from-to)31-34
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume9
Issue number1
DOIs
StatePublished - Jan 1 1986
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combination chemotherapy for advanced colorectal cancer. A pilot study'. Together they form a unique fingerprint.

  • Cite this